[go: up one dir, main page]

WO2010029458A2 - A process for preparing quetiapine fumarate - Google Patents

A process for preparing quetiapine fumarate Download PDF

Info

Publication number
WO2010029458A2
WO2010029458A2 PCT/IB2009/053760 IB2009053760W WO2010029458A2 WO 2010029458 A2 WO2010029458 A2 WO 2010029458A2 IB 2009053760 W IB2009053760 W IB 2009053760W WO 2010029458 A2 WO2010029458 A2 WO 2010029458A2
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine
sodium
quetiapine fumarate
thiazepine
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/053760
Other languages
French (fr)
Other versions
WO2010029458A3 (en
Inventor
Keshav Deo
Ashok Prasad
Dinesh Panchasara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alembic Ltd
Original Assignee
Alembic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Ltd filed Critical Alembic Ltd
Publication of WO2010029458A2 publication Critical patent/WO2010029458A2/en
Publication of WO2010029458A3 publication Critical patent/WO2010029458A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16[b, f]-condensed

Definitions

  • the present invention relates to an improved process for preparing Quetiapine fumarate of formula (I).
  • Quetiapine is used as Antipsychotic. It is antipsychotic, psycholeptics and antidepressant class drug. It is dopamine antagonist and 5HT antagonist. It is used in the treatment of schizophrenia, bipolar diseases and psychosis. It is also used in the treatment of anxiety and depression.
  • Another object of the present invention is to provide a process which gives Quetiapine fumarate with high purity.
  • present invention provides a process for preparation of Quetiapine fumarate (I)
  • present invention provides a process for preparation of Quetiapine fumarate (I)
  • the present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
  • 11-chlorodibenzo [b,f][l,4]thiazepine (III) is heated with l-(2-hydroxyethoxy)ethylpiperazine dihy- drochloride (IV) in the presence of base in sulfolane at about 95 0 C to about 100 0 C for about 4 hours.
  • Other solvent in combination with sulfolane can also be used.
  • a combination of toluene and sulfolane is used as solvent in this reaction step.
  • the base used is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide, l,8-diazobicyclo[5,4,0]undecene, N- benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine and the like or mixtures thereof.
  • An aqueous solution of the base can also be used. After completion of the reaction, the reaction mixture is quenched with water. The reaction mixture is extracted with ethyl acetate. The organic layer is separated and evaporated to dryness to give Quetiapine (V) as viscous oil. A pre -heated solution at about 7O 0 C to about 75 0 C of fumaric acid in methanol is added to a solution of Quetiapine (V) in methanol at about 7O 0 C to about 75 0 C and further heated for 30min at the same temperature. The reaction mixture is cooled to about 5 0 C to about 15 0 C. The separated solid is filtered, washed with chilled methanol and suck dried. The wet cake is used for purification.
  • the present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
  • Impure Quetiapine fumarate means Quetiapine fumarate having HPLC purity less than 99.8%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

The present invention relates to a process for preparing Quetiapine fumarate of formula (I)

Description

Description
Title of Invention: A PROCESS FOR PREPARING QUETIAPINE
FUMARATE
[i]
Field of the invention
[2]
[3] The present invention relates to an improved process for preparing Quetiapine fumarate of formula (I).
Figure imgf000002_0001
[5]
Background of the invention
[6]
[7] The chemical name of Quetiapine is 2-[2-(4-Dibenzo[b,/][l,4] thiazepin-1
1-yl-l-piperazinyl) ethoxy]ethanol and formula is C2IH25N3O2S and molecular weight is 383.51. The drug is used in its fumarate salt. The current pharmaceutical product containing this drug is being sold by Astrazeneca using the tradename Seroquel and Seroquel XR, in the form of oral tablets.
[8]
[9] Quetiapine is used as Antipsychotic. It is antipsychotic, psycholeptics and antidepressant class drug. It is dopamine antagonist and 5HT antagonist. It is used in the treatment of schizophrenia, bipolar diseases and psychosis. It is also used in the treatment of anxiety and depression.
[10]
[11] US patent 4,879,288 describes a process for the preparation of Quetiapine fumarate which is shown in the scheme-I.
Figure imgf000003_0001
Quetiapme V
Figure imgf000003_0002
Quetiapme fumarate (I)
[13] Scheme-I [14] [15] The process involves reacting dibenzo[b,f][l,4] thiazepine-l l(10-H)-one (II) with phosphorous oxychloride in the presence of N,N-dimethylaniline to give imino chloride (III); which is further reacted with l-(2-hydroxyethoxy) ethylpiperazine (IV) in xylene to give Quetiapine (V). Quetiapine is purified by flash chromatography and then converted into its fumarate salt by reacting it with fumaric acid in ethanol to give Quetaipine fumarate (I). The yield and purity obtained by this process is low. Further, this process requires chromatographic purification of Quetiapine before converting it to its fumarate salt. No purification process of Quetiapine fumarate is disclosed in this patent to enhance the purity of Quetiapine fumarate.
[16] [17] It is therefore, a need to develop an easy to operate, industrially feasible process which also provides good yield and high purity of Quetiapine fumarate . The present invention addresses these needs.
[18] [19] Present inventors have directed their research work towards developing a process for the preparation of Quetiapine fumarate which provides good yield and purity. The present inventors observed that using sulfolane as solvent in condensation step of imino chloride (III) with l-(2-hydroxyethoxy)ethylpiperazine (IV) instead of xylene increases yield and purity of quetiapine and which need not require to purify Quetiapine by chromatography before converting it to its fumarate salt.
[20]
Summary of the invention [22] Accordingly, it is an object of the present invention to provide a process for the preparation of Quetiapine fumarate.
[23] [24] Another object of the present invention is to provide a process which gives Quetiapine fumarate with high purity.
[25] [26] Another object of the present invention is to provide a process for the preparation of Quetiapine fumarate which is operationally simple and cost effective.
[27] [28] Accordingly, present invention provides a process for preparation of Quetiapine fumarate (I)
Figure imgf000004_0001
[30] [31] comprising a step of reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III)
Figure imgf000004_0002
[33] [34] with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV) [35]
HN OH
2HCI
IV
[36] [37] in the presence of a base and sulfolane to give Quetiapine (V);
Figure imgf000005_0001
[39] [40] Accordingly, present invention provides a process for preparation of Quetiapine fumarate (I)
Figure imgf000005_0002
[42] [43] comprising steps of: [44] (i) dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II)
Figure imgf000005_0003
[46] [47] with phosphorous oxychloride in the presence of N,N-dimethylaniline in toluene to give 11-chlorodibenzo [b,f][l,4]thiazepine (III);
Figure imgf000005_0004
[49]
[50] (ii) reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III) with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV) HN N ^"-"^ ^^ OH
\ / .2HCI
IV
[52] [53] in the presence of a base and sulfolane to give Quetiapine (V);
Figure imgf000006_0001
[55] [56] (iii) converting Quetiapine (V) to Quetiapine fumarate (I) by reacting it with fumaric acid in methanol.
[57] [58] The present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
[59] (a) heating impure Quetiapine fumarate (I) with methanol [60] (b) adding water dropwise till clear solution obtained [61] (c) cooling the reaction mixture to obtain pure Quetiapine fumarate (I). [62]
Detailed description of the invention
[63] [64] The present invention provides an improved process for preparation of Quetiapine fumarate (I)
Figure imgf000006_0002
[66] comprising steps of: [67] (i) dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II) [68]
Figure imgf000007_0001
[70] with phosphorous oxychloride in the presence of N,N-dimethylaniline in toluene to give 11-chlorodibenzo [b,f][l,4] thiazepine (III);
Figure imgf000007_0002
[72] [73] (ii) reacting 11-chlorodibenzo [b,f][l,4] thiazepine (III) with l-(2-hydroxyethoxy) ethylpiperazine dihydrochloride (IV)
[74]
HN OH
2HCI
IV
[75] [76] in the presence of a base and sulfolane to give Quetiapine (V);
Figure imgf000007_0003
[78] [79] (iii) converting Quetiapine (V) to Quetiapine fumarate (I) by reacting it with fumaric acid in methanol.
[80] [81] The synthetic reaction scheme of the present invention is shown in the scheme-II. [82]
Figure imgf000008_0001
Quetiapine v
Figure imgf000008_0002
Quetiapine fumarate (I)
[83] Scheme-II [84] [85] In the process of present invention, dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II) is heated with Phosphorous oxychloride in the presence of N,N-Dimethyl aniline in toluene at about 11O0C to about 1150C for 5 to 6 hours. After completion of reaction, organic layer is washed with water. The solvent from organic layer is distilled out under reduced pressure at about 450C to about 5O0C to give 11-chlorodibenzo [b,f][l,4]thiazepine (III) which is used as such for next step. 11-chlorodibenzo [b,f][l,4]thiazepine (III) is heated with l-(2-hydroxyethoxy)ethylpiperazine dihy- drochloride (IV) in the presence of base in sulfolane at about 950C to about 1000C for about 4 hours. Other solvent in combination with sulfolane can also be used. For example a combination of toluene and sulfolane is used as solvent in this reaction step. The base used is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide, l,8-diazobicyclo[5,4,0]undecene, N- benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine and the like or mixtures thereof. An aqueous solution of the base can also be used. After completion of the reaction, the reaction mixture is quenched with water. The reaction mixture is extracted with ethyl acetate. The organic layer is separated and evaporated to dryness to give Quetiapine (V) as viscous oil. A pre -heated solution at about 7O0C to about 750C of fumaric acid in methanol is added to a solution of Quetiapine (V) in methanol at about 7O0C to about 750C and further heated for 30min at the same temperature. The reaction mixture is cooled to about 50C to about 150C. The separated solid is filtered, washed with chilled methanol and suck dried. The wet cake is used for purification.
[86]
[87] The present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
[88] (a) heating impure Quetiapine fumarate (I) with methanol
[89] (b) adding water dropwise till clear solution obtained
[90] (c) cooling the reaction mixture to obtain pure Quetiapine fumarate (I).
[91]
[92] Impure Quetiapine fumarate' means Quetiapine fumarate having HPLC purity less than 99.8%.
[93] In the purification of Quetiapine fumarate, methanol is added to the wet cake of impure Quetiapine fumarate obtained in above process and heated at about 650C to about 7O0C. D. M. Water is added drop wise at the same temperature till clear solution is obtained. The reaction mixture is stirred for 30 min at the same temperature and then cooled to about 50C to about 15 0C. The separated solid is filtered, washed with chilled methanol and suck dried. The solid is dried under vacuum at about 550C to about 6O0C to give pure Quetiapine fumarate (I)
[94] The following examples illustrate the invention further. It should be understood, however, that the invention is not confined to the specific limitations set forth in the individual examples but rather to the scope of the appended claims.
[95]
[96] Example-1
[97]
[98] Preparation of 11-chlorodibenzo [b,f][l,4]thiazepine (III)
[99] dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II) (100 g) was heated with phosphorous oxychloride (67.46 g) in the presence of N,N-Dimethyl aniline (106.63 g) in toluene (500 ml) at 11O0C to 1150C for 5 to 6 hours. After completion of the reaction, organic layer was washed twice with water (2x 200 ml). The solvent from organic layer was distilled out under reduced pressure at 450C to 5O0C to give residue 11-chlorodibenzo [b,f][l,4]thiazepine (III) which was used as such for next step.
[100]
[101] Example-2
[102]
[103] Preparation of Quetiapine Base (V)
[104] Residue 11-chlorodibenzo [b,f][l,4]thiazepine (III) obtained from Example-1 was heated with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV) (119.65 g) in the presence of potassium carbonate (213.12 g) in sulfolane (400 ml) at 950C to 1000C for about 4 hours. After completion of reaction, the reaction mixture was quenched with D. M. Water (1000 ml). The reaction mixture is extracted with ethyl acetate (2x300 ml). Organic layer is separated evaporated to dryness under vacuum to give Quetiapine (V) as viscous oil which was used as such for the next step.
[105]
[106] Example-3
[107]
[108] Preparation of Quetiapine Fumarate (I)
[109] A pre-heated solution at 7O0C to 750C of Fumaric acid (26.55 g) in methanol (300 ml) was added to the solution of Quetiapine [obtained in Example-2] in methanol(300 ml) at 7O0C to 750C. The reaction mixture was stirred for 30 min at 7O0C to 750C. The reaction mixture was cooled to 150C. The separated solid was filtered, washed with chilled methanol (100 ml) and suck dried. The wet cake of Quetiapine fumarate was used as such for the next step.
[HO]
[111] Example-4
[112]
[113] Purification of Quetiapine Fumarate (I)
[114] Quetiapine fumarate wet cake obtained from Example-4 was heated in methanol
(1200 ml) at 650C to 7O0C. D. M. Water (approximately 50 ml) was added drop wise at the same temperature till clear solution was obtained. The reaction mixture was stirred for 30 min at 65-7O0C. The reaction mixture was cooled to 150C. The separated solid was filtered, washed with chilled methanol (100 ml) and dried under vacuum at 550C to 6O0C to give pure Quetiapine fumarate (122.0 g)
[115] Overall yield: 55.56%
[116] Purity (by HPLC): 99.84%
[117]

Claims

Claims
[Claim 1] 1. A process for preparation of Quetiapine fumarate (I)
Figure imgf000011_0001
comprising a step of reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III)
Figure imgf000011_0002
with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
HN OH
2HCI
IV in the presence of a base and sulfolane to give Quetiapine (V);
Figure imgf000011_0003
[Claim 2] 2. A process for preparation of Quetiapine fumarate (I)
Figure imgf000012_0001
comprising steps of:
(i) dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II)
Figure imgf000012_0002
with phosphorous oxychloride in the presence of N,N-dimethylaniline in toluene to give 11-chlorodibenzo [b,f][l,4]thiazepine (III);
Figure imgf000012_0003
(ii) reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III) with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
HN "OH
2HCI
IV in the presence of a base and sulfolane to give Quetiapine (V);
Figure imgf000012_0004
(iii) converting Quetiapine (V) to Quetiapine fumarate (I) by reacting it with fumaric acid in methanol
[Claim 3] 3. The process as claimed in claim 1 or 2, wherein the base is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide,
1 ,8-diazobicyclo[5,4,0]undecene, N-benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine or mixtures thereof.
[Claim 4] 4. A process for purification of Quetiapine fumarate (I) comprising steps of
(a) heating impure Quetiapine fumarate (I) with methanol
(b) adding water dropwise till clear solution obtained
(c) cooling the reaction mixture to obtain pure Quetiapine fumarate (I)
[Claim 5] 5. A process for preparation of Quetiapine fumarate (I)
Figure imgf000013_0001
comprising a step of reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III)
Figure imgf000013_0002
with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
Figure imgf000013_0003
in the presence of a base and a mixture of sulfolane and toluene to give Quetiapine (V);
Figure imgf000014_0001
[Claim 6] 6. The process as claimed in claim 5, wherein the base is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium iso- propoxide, potassium tert-butoxide, l,8-diazobicyclo[5,4,0]undecene, N-benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine or mixtures thereof .
PCT/IB2009/053760 2008-09-09 2009-08-28 A process for preparing quetiapine fumarate Ceased WO2010029458A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1897/MUM/2008 2008-09-09
IN1897MU2008 2008-09-09

Publications (2)

Publication Number Publication Date
WO2010029458A2 true WO2010029458A2 (en) 2010-03-18
WO2010029458A3 WO2010029458A3 (en) 2011-01-27

Family

ID=42005565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/053760 Ceased WO2010029458A2 (en) 2008-09-09 2009-08-28 A process for preparing quetiapine fumarate

Country Status (1)

Country Link
WO (1) WO2010029458A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102432562A (en) * 2011-11-28 2012-05-02 海南美兰史克制药有限公司 Quetiapine fumarate compound and novel preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516603D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102432562A (en) * 2011-11-28 2012-05-02 海南美兰史克制药有限公司 Quetiapine fumarate compound and novel preparation method thereof

Also Published As

Publication number Publication date
WO2010029458A3 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
WO2009010988A1 (en) An improved, industrially viable process for the preparation of high purity paliperidone
US20060063927A1 (en) Processes for preparing quetiapine and salts thereof
JP6142459B2 (en) Process for the preparation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and its precursor
JP5819284B2 (en) Method for producing olopatadine
WO2008001188A2 (en) An improved process for the preparation of substantially pure aripiprazole
US20140187568A1 (en) Crystalline forms of bosentan salts and processes for their preparation
WO2010029458A2 (en) A process for preparing quetiapine fumarate
CZ20013658A3 (en) Synthesis and crystallization of compounds containing piperazine ring
US20130184490A1 (en) Process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid
US7045621B1 (en) Process for producing dibenzothiazepine derivatives
EP2245021B1 (en) A process for the preparation of quetiapine
WO2007020011A1 (en) Processes for the preparation of thiazepines
EP2370432A2 (en) A process for preparing quetiapine fumarate
PL195728B1 (en) Method for manufacture of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine
WO2008152434A1 (en) Synthesis for the preparation of quetiapine
EP1948628A1 (en) Quetiapine hemifumarate purification by crystallization
WO2003000670A1 (en) A11-piperazinyldibenzo (b, f) (1, 4) oxazepines and thiazepines as atypical antipsychotic agents having low affinity for the d2 receptor
JP4238978B2 (en) Benzazepine compounds and process for producing the same
US20120071649A1 (en) Process for the preparation of quetiapine fumarate
US20120259116A1 (en) Novel Process for the Preparation of Paliperidone
EP4281076A1 (en) Processes for purification of bictegravir intermediates
EP2749556B1 (en) An improved process for the preparation of pure cyamemazine and salts thereof
CN119285569A (en) A type of five-membered nitrogen heterocyclic derivative and its preparation method and application
WO2010085976A1 (en) Process for the synthesis of quetiapine
HU185725B (en) Process for preparing 1,5-benzothiazepine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09812763

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09812763

Country of ref document: EP

Kind code of ref document: A2